Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK invests £1.25mm in hearing loss spin-out Autifony, out-licenses candidates

Executive Summary

For a 25.4% stake, GlaxoSmithKline PLC’s Glaxo Group Ltd. is investing £1.25mm ($2.06mm) into its hearing loss spin-out Autifony Therapeutics Ltd., which is issuing the Big Pharma 850k A ordinary shares.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies